aFraxis afraxis.com


Public list: BIO 2016 (619) Pharma Startups (4743) Neuroscience Startups (947)

Afraxis is discovering and developing drugs to treat diseases of the central nervous system, including schizophrenia, Alzheimer's disease, Fragile X syndrome and autism spectrum disorders. Recent scientific discoveries have linked these disorders to underlying defects in the development and function of specialized structures of the neural synapse, called dendritic spines. Afraxis is leveraging this discovery to develop drug treatments that control dendritic spine function. The company's lead pro...Show all

Afraxis is discovering and developing drugs to treat diseases of the central nervous system, including schizophrenia, Alzheimer's disease, Fragile X syndrome and autism spectrum disorders. Recent scientific discoveries have linked these disorders to ...Show all

Company (Alive / Active)

Phone: 858-768-7800

Fax:

11099 N Torrey Pines Road
Suite 290
La Jolla, 92037
California, United States

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
aFraxis $4.7M Apr 3, 2012
See all 16 competitors

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related aFraxis Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 2 investors

Competitors

Company Status Description Investors

Arcion Therapeutics

Baltimore, Maryland, United States
Alive / ActiveArcion Therapeutics applies breakthroughs in neuroscience to advance the treatment of chronic pain. The company focuses on topical treatments to provide pain relief with convenient application and reduced systemic side effects. Arcion's core technology is based on research which showed that in many neuropathic pain conditions, the signal that triggers pain actually arises at the level of the skin. This finding provides a strong biological rationale for developing topically delivered drugs to tar...Show allLogin to see details

Cequent Pharmaceuticals

Cambridge, Massachusetts, United States
AcquiredCequent is an early-stage biopharmaceutical company developing new clinically compatible therapies based on RNA interference (RNAi). Cequent is focusing its efforts on the pre-clinical development of products to treat gastrointestinal diseases, including familial polyposis, inflammatory bowel disease and colon cancer.Login to see details
See all 16 competitors